Ken Griffin Paratek Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2023

Aug 14, 2023
SELL
$1.52 - $2.8 $19,608 - $36,120
-12,900 Reduced 70.88%
5,300 $11,000
Q1 2023

May 15, 2023
BUY
$1.37 - $2.54 $13,015 - $24,130
9,500 Added 109.2%
18,200 $46,000
Q4 2022

Feb 14, 2023
SELL
$1.67 - $2.51 $9,519 - $14,306
-5,700 Reduced 39.58%
8,700 $16,000
Q3 2022

Nov 14, 2022
SELL
$1.96 - $2.93 $10,192 - $15,236
-5,200 Reduced 26.53%
14,400 $37,000

Others Institutions Holding PRTK

# of Institutions
4
Shares Held
1.54M
Call Options Held
0
Put Options Held
0
View Full List

About Paratek Pharmaceuticals, Inc.

PRTK Quotes by TradingView
  • Ticker PRTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,862,500
  • Description
  • Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...
More about PRTK
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email